Physician profile
Ryan G White
NPI 1912932799
$8,996.67
in general payments reported to CMS, 2019-2025
41 companies · $631 in 2025
The $631 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $4,642 · 2021: $1,433 · 2022: $357 · 2023: $720 · 2024: $649 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $4,453.92 | 2019-2020 | |
| Teleflex LLC | $1,298.57 | 2021-2024 | Urolift |
| Abbvie INC. | $522.66 | 2019-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $295.31 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $241.80 | 2019-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $238.15 | 2023-2025 | Prolaris |
| Medtronic, INC. | $171.52 | 2022-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $169.61 | 2020-2025 | Watchman Access System, General - Female Sui |
| Sumitomo Pharma America, INC. | $167.88 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $149.19 | 2021-2024 | |
| Coloplast Corp | $143.26 | 2019-2024 | |
| Pfizer INC. | $107.98 | 2019-2025 | |
| Accord Healthcare, INC. | $91.94 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $71.36 | 2024-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $60.96 | 2019-2023 | Edex, Aveed, Xiaflex |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.